Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Mar 31;11(6):272.
doi: 10.21037/atm-2022-81. Epub 2023 Jan 19.

PARP inhibitors, use early in the first-line maintenance therapy setting but with caution

Elena Giudice  1   2 , Yong Man Kim  3 , Jung-Min Lee  1
Affiliations
Editorial

PARP inhibitors, use early in the first-line maintenance therapy setting but with caution

Elena Giudice et al. Ann Transl Med. .
No abstract available

Keywords: Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis); biomarker-guided cancer treatment; mechanism of drug resistance; optimal sequencing for cancer treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-2022-81/coif). JML received grant (No. ZIA BC011525) from National Cancer Institute Center for Cancer Research (NCI CCR) and National Institutes of Health. The other authors have no conflicts of interests to declare.

Comment on

References

    1. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2018;379:2495-505. 10.1056/NEJMoa1810858 - DOI - PubMed
    1. González-Martín A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2019;381:2391-402. 10.1056/NEJMoa1910962 - DOI - PubMed
    1. Del Campo JM, Matulonis UA, Malander S, et al. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol 2019;37:2968-73. 10.1200/JCO.18.02238 - DOI - PMC - PubMed
    1. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:1274-84. 10.1016/S1470-2045(17)30469-2 - DOI - PubMed
    1. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:1949-61. 10.1016/S0140-6736(17)32440-6 - DOI - PMC - PubMed